$HURA

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 3.02 Unregistered Sale of Equity Securities . As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreeme

TuHURA Biosciences (NASDAQ:HURA) reported Q2 2026 results for the quarter ended June 30, 2026, and outlined upcoming FDA and clinical milestones. Cash was $1.0M at June 30. R&D expenses were $6.6M. The company also described a $50M non-convertible term credit facility from its largest shareholder and expected orphan drug designations and trial starts in 2H 2026-2027.

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resista

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. 8-K 0001498382 false TuHURA Biosciences, Inc./NV 0001498382 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earlies

TuHURA Biosciences ( NASDAQ:HURA ) , a biotechnology company focused on immuno-oncology therapies, released its second quarter results on August 14, 2025. The big headlines included the start of a pivotal Phase 3 clinical trial for IFx-2.0, a new product candidate, under a unique regulatory ...

August 11, 2025 records indicate that Representative Laurel Lee filed a sale of Alibaba Gr Hldgs BABA, valued between $101,002 and $265,000. According to the August filing, the transaction occurred on December 29, 2023. Currently, Alibaba Gr Hldgs shares are trading up 1.21% at $120.08.